Abbott Laboratories: PharmaVitae Profile

Introduction

This analysis examines the historical and forecast performance for Abbott in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs.

Features and benefits

* Gain insight into Abbott's strategic outlook across the next 6 years
* Analyze company sales forecasts by product, therapy area, lifecycle stage, geography, molecule type and source.

Highlights

Strategic insight into the prospects for Abbott over the next six years. Picking out key strengths, weaknesses, opportunities and threats and evaluating the company's prescription pharmaceuticals outlook using a variety of cuts of the historical and forecast sales.

Your key questions answered

* Benchmark Abbott's performance against key rivals in the prescription pharmaceutical sector
* Discover how Abbott has utilized M&A to become one of the world's largest multi-disciplinary healthcare companies.

[Studien Infos ausblenden]

Executive Summary
Key findings
Abbott’s prescription pharmaceutical sales outlook
Abbott financial outlook
Key developments
[Missing title]
Upcoming developments
SWOT analysis
Strengths
Weaknesses
Opportunities
Threats
ABOUT THIS PROFILE
PharmaVitae Explorer database
Chapter structure
Strategic insight
Company introduction
Company sales
Company financials
Key products
Data sourcing
Analyst consensus
STRATEGIC INSIGHT
Key findings
Strategic insight
[Missing title]
Abbott has the biggest share of the autoimmune disorder market
Weak pipeline could lead to long-term growth
COMPANY INTRODUCTION
Key findings
Background
Key corporate developments
Post-war proliferation
Collaboration, diversification, and expansion
M&A history
Knoll Pharmaceuticals
Guidant's vascular business
Kos Pharmaceuticals
Advanced Medical Optics
Solvay
Facet Biotech
Piramal Healthcare Solutions
Current corporate structure
Pharmaceuticals
Nutritionals
Diagnostics
Vascular
Other
COMPANY SALES
Key findings
Prescription pharmaceutical sales and growth rate analysis, 2004–16
Product analysis
Product analysis, 2004–10
Product analysis, 2010–16
Therapy area analysis
Geographic analysis
Launch/core/expiry analysis
Explanation of launch/core/expiry analysis
Launch analysis, 2010–16
Core analysis, 2010–16
Expiry analysis, 2010–16
Generics analysis, 2010–16
Launch/core/expiry configuration, 2010–16
Molecule type analysis
Externalization analysis
COMPANY FINANCIALS
Key findings
Reconciliation between PharmaVitae-formatted prescription pharmaceutical sales and company-reported total sales, 2004–10
Operating costs and profit analysis
Operating costs and profit analysis, 2004–10
Operating cost ratio and profit margin analysis, 2004–10
Operating cost ratio and profit margin analysis, 2010–16
Operating costs and profit analysis, 2010–16
PRODUCT AND PIPELINE ANALYSIS
Overview
Humira
TriCor/Trilipix
Sevorane
Lupron
Kaletra
ABT874
Niaspan franchise
Abbott pipeline overview
APPENDIX
References
Abbreviations

[Inhaltsverzeichnis ausblenden]